

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron

Nature Medicine

28, 1063-1071

DOI: [10.1038/s41591-022-01753-y](https://doi.org/10.1038/s41591-022-01753-y)

Citation Report

#	ARTICLE	IF	CITATIONS
4	COVID-19 Vaccine: Between Myth and Truth. <i>Vaccines</i> , 2022, 10, 349.	2.1	12
8	Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	1.1	4
9	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac124.	0.4	25
10	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
12	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.	13.5	179
13	Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. <i>BMJ, The</i> , 2022, 376, e069761.	3.0	393
14	SARS-CoV-2 Omicron variant: Immune escape and vaccine development. <i>MedComm</i> , 2022, 3, e126.	3.1	74
15	It is not too late to achieve global covid-19 vaccine equity. <i>BMJ, The</i> , 2022, 376, e070650.	3.0	62
19	Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD. <i>MedComm</i> , 2022, 3, e130.	3.1	18
20	SARS-CoV-2-specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge. <i>JCI Insight</i> , 2022, 7, .	2.3	15
21	Quantifying excess deaths among solid organ transplant recipients in the COVID-19 era. <i>American Journal of Transplantation</i> , 2022, 22, 2077-2082.	2.6	26
22	Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges. <i>Metabolism Open</i> , 2022, 14, 100180.	1.4	41
24	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	10
25	The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines. <i>Vaccines</i> , 2022, 10, 591.	2.1	27
26	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	62
27	Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 124.	7.1	15
29	COVID-19: Omicron – the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. <i>Microbial Biotechnology</i> , 2022, 15, 1927-1939.	2.0	41
30	Omicron – The new SARS-CoV-2 challenge?. <i>Reviews in Medical Virology</i> , 2022, 32, e2358.	3.9	28

#	ARTICLE	IF	CITATIONS
31	Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative caseâ€“control study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 689-699.	5.2	108
32	Advances in COVID-19 mRNA vaccine development. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 94.	7.1	177
33	Protection of Hamsters Challenged with SARS-CoV-2 Delta Variant after Two Doses of Adjuvanted SARS-CoV-2 Stabilized Prefusion Spike Protein (S-2P) and a Single Dose of Beta Variant S-2P. <i>Journal of Infectious Diseases</i> , 2022, , .	1.9	5
34	The Emergence of Omicron SARS-CoV-2 Variant (B.1.1.529): The Latest Episode in the COVID-19 Pandemic with a Global Riposte. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	2
35	Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	26
36	Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases. <i>JCI Insight</i> , 2022, 7, .	2.3	32
37	Would New SARS-CoV-2 Variants Change the War against COVID-19?. <i>Epidemiologia</i> , 2022, 3, 229-237.	1.1	3
39	Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines. <i>Mucosal Immunology</i> , 2022, 15, 584-594.	2.7	41
40	Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization. <i>Vaccine</i> , 2022, 40, 3516-3527.	1.7	69
41	Tâ€“cell responses to SARSâ€“CoVâ€“2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine. <i>Journal of Medical Virology</i> , 2022, 94, 3998-4004.	2.5	20
42	Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant â€“ United States, February 14â€“March 27, 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 633-637.	9.0	37
43	Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination Status. <i>JAMA Network Open</i> , 2022, 5, e229317.	2.8	145
44	Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study. <i>PLoS ONE</i> , 2022, 17, e0267824.	1.1	15
45	Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection. , 2022, 1, .		6
46	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
47	Public health impact of covid-19 vaccines in the US: observational study. <i>BMJ</i> , The, 2022, 377, e069317.	3.0	102
48	mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	2
50	Role of COVID-19 Vaccines in SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	37

#	ARTICLE	IF	CITATIONS
53	Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. <i>BMJ, The</i> , 0, , e069989.	3.0	78
54	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149
55	Recent insights into SARSâ€CoVâ€2 omicron variant. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	29
56	Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1313-1320.	4.6	58
57	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. <i>Nature Communications</i> , 2022, 13, .	5.8	188
58	Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects. <i>Current Opinion in Immunology</i> , 2022, 77, 102214.	2.4	7
59	Antibody testing as the guide to our living with COVID-19. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2022, 33, 338-346.	0.1	0
61	Understanding COVID-19 Vaccines Today: Are T-cells Key Players?. <i>Vaccines</i> , 2022, 10, 904.	2.1	7
62	Association Between Vaccination Coverage Disparity and the Dynamics of the COVID-19 Delta and Omicron Waves in the US. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	21
63	A Macro-Level Association of Vaccination Rate with the Number of Confirmed COVID-19 Cases in the United States and Japan. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7435.	1.2	0
64	Outcome of infection with omicron <sc>SARSâ€CoV</sc>â€2 variant in patients with hematological malignancies: An <sc>EPICOVIDEHA</sc> survey report. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	39
65	Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. <i>Nature Medicine</i> , 2022, 28, 1715-1722.	15.2	29
66	Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3. <i>Immunity</i> , 2022, 55, 1501-1514.e3.	6.6	59
67	Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 12, 100297.	1.5	37
68	COVID-19 infection, and reinfection, and vaccine effectiveness against symptomatic infection among health care workers in the setting of omicron variant transmission in New Delhi, India. , 2022, 3, 100023.		21
69	OMICRON: Virology, immunopathogenesis, and laboratory diagnosis. <i>Journal of Gene Medicine</i> , 2022, 24, .	1.4	33
70	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. <i>New England Journal of Medicine</i> , 2022, 387, 21-34.	13.9	368
71	Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis. <i>Vaccine</i> , 2022, 40, 4742-4747.	1.7	9

#	ARTICLE	IF	CITATIONS
72	SARS-CoV-2: phenotype, genotype, and characterization of different variants. Cellular and Molecular Biology Letters, 2022, 27, .	2.7	12
74	SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2267-2273.	2.0	10
76	Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science, 2022, 377, .	6.0	241
77	COVID-19 Vaccines: Update of the vaccines in use and under development. Vacunas, 2022, , .	1.1	6
78	Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. Nature Medicine, 2022, 28, 1933-1943.	15.2	243
79	Monitoring the COVID-19 immune landscape in Japan. International Journal of Infectious Diseases, 2022, 122, 300-306.	1.5	5
80	Increased Secondary Attack Rates among the Household Contacts of Patients with the Omicron Variant of the Coronavirus Disease 2019 in Japan. International Journal of Environmental Research and Public Health, 2022, 19, 8068.	1.2	12
81	Antibody efficacy of inactivated vaccine boosters (CoronaVac) against Omicron variant from a 15-month follow-up study. Journal of Infection, 2022, 85, e119-e121.	1.7	8
82	BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. New England Journal of Medicine, 2022, 387, 227-236.	13.9	68
83	Dawn of the hybrid immunity era in long-term care facilities. The Lancet Healthy Longevity, 2022, 3, e451-e452.	2.0	0
84	Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. International Journal of Molecular Sciences, 2022, 23, 7675.	1.8	9
85	SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. Cell Host and Microbe, 2022, 30, 1231-1241.e6.	5.1	55
86	Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences. Vaccines, 2022, 10, 1068.	2.1	9
87	Quantifying the immunological distinctiveness of emerging SARS-CoV-2 variants in the context of prior regional herd exposure. , 0, , .		0
88	Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine. Scientific Reports, 2022, 12, .	1.6	4
89	Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study. BMJ, The, 0, , e071502.	3.0	111
90	A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains. Journal of Clinical Medicine, 2022, 11, 4164.	1.0	15
91	The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis. Frontiers in Public Health, 0, 10, .	1.3	27

#	ARTICLE	IF	CITATIONS
92	Differences in Immunological Evasion of the Delta (B.1.617.2) and Omicron (B.1.1.529) SARS-CoV-2 Variants: A Retrospective Study on the Veneto Region's Population. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8179.	1.2	6
93	Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. <i>EBioMedicine</i> , 2022, 82, 104158.	2.7	128
94	Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records. <i>BMJ</i> , The, 0, , e071249.	3.0	31
95	Evaluation and Clinical Validation of Guanidine-Based Inactivation Transport Medium for Preservation of SARS-CoV-2. <i>Advances in Pharmacological and Pharmaceutical Sciences</i> , 2022, 2022, 1-9.	0.7	1
96	Transmissibility of SARS-CoV-2 B.1.1.214 and Alpha Variants during 4 COVID-19 Waves, Kyoto, Japan, January 2020–June 2021. <i>Emerging Infectious Diseases</i> , 2022, 28, .	2.0	4
97	Social and Behavioral Factors Associated with Lack of Intent to Receive COVID-19 Vaccine, Japan. <i>Emerging Infectious Diseases</i> , 2022, 28, 1909-1910.	2.0	1
98	Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants. <i>International Journal of Biological Sciences</i> , 2022, 18, 4642-4647.	2.6	4
99	Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron and Delta-related outpatient illness among adults, October 2021–February 2022. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 975-985.	1.5	11
100	COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects. <i>Vaccines</i> , 2022, 10, 1223.	2.1	12
101	Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S. <i>Npj Vaccines</i> , 2022, 7, .	2.9	13
102	Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination. <i>Vaccines</i> , 2022, 10, 1163.	2.1	4
103	HIV and COVID-19: A Tale of Two Pandemics. <i>Current HIV Research</i> , 2022, 20, 344-349.	0.2	1
104	COVID-19 and vaccination: myths vs science. <i>Expert Review of Vaccines</i> , 2022, 21, 1603-1620.	2.0	23
105	Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans. <i>BMJ Open</i> , 2022, 12, e063935.	0.8	16
106	A historical analysis of vaccine mandates in the United States military and its application to the COVID-19 vaccine mandate. <i>Vaccine</i> , 2022, 40, 7500-7504.	1.7	4
107	Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
108	A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
109	Humoral response to SARS-CoV-2 mRNA vaccination in previous non-responder kidney transplant recipients after short-term withdrawal of mycophenolic acid. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	10

#	ARTICLE	IF	CITATIONS
110	Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients. <i>IScience</i> , 2022, 25, 104990.	1.9	8
111	Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021â€“2022: A Naturalistic Case-Control Study in Sweden. <i>Vaccines</i> , 2022, 10, 1273.	2.1	1
112	Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. <i>Nature Communications</i> , 2022, 13, .	5.8	87
113	Facing the Omicron variantâ€”how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	32
114	Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2) <i>Tj ETQq0 0 0 2gBT /Over12 10 Tf e108-e115.</i>	0.2	0
115	Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2693-2700.	1.3	41
116	Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a highly vaccinated Asian setting: a test-negative design study. <i>Clinical Microbiology and Infection</i> , 2023, 29, 101-106.	2.8	16
117	Description of Hospitalizations due to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Based on Vaccination Status. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	5
119	Development and Validation of HPLC-UV Method for the Determination of Favipiravir in Human Plasma. <i>Drug Development and Registration</i> , 2022, 11, 220-229.	0.2	6
122	Real-Time Survey of Vaccine Safety of the mRNA-1273 SARS-CoV-2 Vaccine in Workplace Vaccination at Keio University. <i>Vaccines</i> , 2022, 10, 1461.	2.1	1
123	Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103762.	1.4	0
124	SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain. <i>Emerging Infectious Diseases</i> , 2022, 28, 1999-2008.	2.0	12
125	Individual-based modeling of COVID-19 transmission in college communities. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 13861-13877.	1.0	2
126	Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States. <i>Mathematical Biosciences and Engineering</i> , 2022, 20, 179-212.	1.0	6
127	Enhanced Enzymatically Amplified Metallization on Nanostructured Surfaces for Multiplexed Point-of-Care Electrical Detection of COVID-19 Biomarkers. <i>Small</i> , 2022, 18, .	5.2	4
129	Clinical Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Relative to Delta in British Columbia, Canada: A Retrospective Analysis of Whole-Genome Sequenced Cases. <i>Clinical Infectious Diseases</i> , 2023, 76, e18-e25.	2.9	15
130	COVID-19 Vaccine Effectiveness against Omicron Variant among Underage Subjects: The Veneto Regionâ€™s Experience. <i>Vaccines</i> , 2022, 10, 1362.	2.1	7
132	Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. <i>Nature Communications</i> , 2022, 13, .	5.8	89

#	ARTICLE	IF	CITATIONS
133	Relative Hypercoagulopathy of the SARS-CoV-2 Beta and Delta Variants when Compared to the Less Severe Omicron Variants Is Related to TEG Parameters, the Extent of Fibrin Amyloid Microclots, and the Severity of Clinical Illness. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 858-868.	1.5	26
134	COVID-19 and isolation: Risks and implications in the scenario of new variants. <i>Brazilian Journal of Infectious Diseases</i> , 2022, 26, 102703.	0.3	2
135	New insights into human immune memory from SARS-CoV-2 infection and vaccination. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 0, , .	2.7	5
137	Salivary IgAs and Their Role in Mucosal Neutralization of SARS-CoV-2 Variants of Concern. <i>Journal of Clinical Microbiology</i> , 2022, 60, .	1.8	7
138	Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 177-182.	4.6	13
139	Global Implications for COVID-19 Vaccine Series Completion: Insights from Real-World Data from the United States. <i>Vaccines</i> , 2022, 10, 1561.	2.1	0
140	Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine. <i>Journal of the Formosan Medical Association</i> , 2023, 122, 121-131.	0.8	9
141	The way forward to achieve high COVID-19 vaccination and revaccination coverage in a city amid a period of tranquility. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	5
143	An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2. <i>Science China Life Sciences</i> , 0, , .	2.3	2
144	High mortality and morbidity among vaccinated residents infected with the SARS-CoV-2 Omicron variant during an outbreak in a nursing home in Kyoto City, Japan. <i>American Journal of Infection Control</i> , 2023, 51, 800-806.	1.1	7
146	Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	5
147	Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003992.	3.9	83
148	Lack of correlation between school mask mandates and paediatric COVID-19 cases in a large cohort. <i>Journal of Infection</i> , 2022, 85, 671-675.	1.7	12
149	Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults. <i>Clinical Infectious Diseases</i> , 2023, 76, 252-262.	2.9	7
151	Evaluating the efficacy and safety of SpikoGen [®] , an Advax-CpG55.2- α 2 adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial. <i>Clinical Microbiology and Infection</i> , 2023, 29, 215-220.	2.8	25
152	Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. <i>JAMA Network Open</i> , 2022, 5, e2232760.	2.8	177
154	Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment. <i>Applied Mathematical Modelling</i> , 2023, 114, 447-465.	2.2	23
156	Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals. <i>Scientific Reports</i> , 2022, 12, .	1.6	8

#	ARTICLE	IF	CITATIONS
157	Adaptationâ€Proof SARSâ€CoVâ€ Vaccine Design. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	7
159	The paradigm of immune escape by SARS-CoV-2 variants and strategies for repositioning subverted mAbs against escaped VOCs. <i>Molecular Therapy</i> , 2022, 30, 3101-3105.	3.7	4
160	A Bivalent Omicron-Containing Booster Vaccine against Covid-19. <i>New England Journal of Medicine</i> , 2022, 387, 1279-1291.	13.9	401
161	Ad5â€nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	10
162	Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. <i>Nature Medicine</i> , 2022, 28, 2388-2397.	15.2	89
163	Protection against Omicron from Vaccination and Previous Infection in a Prison System. <i>New England Journal of Medicine</i> , 2022, 387, 1770-1782.	13.9	40
164	Real-Time Monitoring of the Effectiveness of Six COVID-19 Vaccines against Laboratory-Confirmed COVID-19 in Hungary in 2021 Using the Screening Method. <i>Vaccines</i> , 2022, 10, 1824.	2.1	6
165	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
166	Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster. <i>IScience</i> , 2022, 25, 105465.	1.9	2
167	Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study. <i>BMJ, The</i> , 0, , e072065.	3.0	54
168	Nucleic Acid Vaccines against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 1849.	2.1	10
169	Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection. <i>Npj Vaccines</i> , 2022, 7, .	2.9	12
170	Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. <i>Science</i> , 2022, 378, 619-627.	6.0	117
172	Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222. <i>Vaccines</i> , 2022, 10, 1701.	2.1	3
173	Effectiveness of Inactivated COVID-19 Vaccines against COVID-19 Caused by the SARS-CoV-2 Delta and Omicron Variants: A Retrospective Cohort Study. <i>Vaccines</i> , 2022, 10, 1753.	2.1	6
174	COVID-19 Vaccine Booster Dose Acceptance: Systematic Review and Meta-Analysis. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 298.	0.9	39
175	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. <i>Nature Medicine</i> , 2023, 29, 247-257.	15.2	98
176	Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	3

#	ARTICLE	IF	CITATIONS
177	SARS-CoV-2 evolves to reduce but not abolish neutralizing action. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6
178	Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. <i>New England Journal of Medicine</i> , 2022, 387, 1673-1687.	13.9	63
179	Year 3 of COVID-19: Harsh Truths, Brutal Realities, and Glimmers of Hope. <i>Mayo Clinic Proceedings</i> , 2022, 97, 2324-2332.	1.4	3
180	Inhalation of Low Molecular Weight Heparins as Prophylaxis against SARS-CoV-2. <i>MBio</i> , 2022, 13, .	1.8	4
181	Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. <i>International Journal of Infectious Diseases</i> , 2022, 125, 58-60.	1.5	7
182	Intramuscular injection of a mixture of COVID-19 peptide vaccine and tetanus vaccine in horse induced neutralizing antibodies against authentic virus of SARS-CoV-2 Delta variant. <i>Vaccine: X</i> , 2022, 12, 100230.	0.9	1
183	The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What. <i>Vaccines</i> , 2022, 10, 1924.	2.1	8
184	COVID-19 vaccine response and safety in patients with cancer: An overview of systematic reviews. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
185	High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	24
187	Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters. <i>Nature Communications</i> , 2022, 13, .	5.8	11
188	Analysis of COVID-19 Vaccination Status Among Parents of Hospitalized Children Younger Than 5 Years With SARS-CoV-2 Infection During the Delta and Omicron Waves. <i>JAMA Network Open</i> , 2022, 5, e2242295.	2.8	0
189	Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. <i>Expert Review of Vaccines</i> , 2023, 22, 1-16.	2.0	21
190	Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 0, , .	1.2	3
191	Changes in spike protein antibody titer over 90 days after the second dose of SARS-CoV-2 vaccine in Japanese dialysis patients. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	0
192	Antibodies as drugs” a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2023, 1519, 153-166.	1.8	2
193	A review of COVID vaccines: success against a moving target. <i>British Medical Bulletin</i> , 2022, 144, 12-44.	2.7	5
194	Developing Next-Generation Protein-Based Vaccines Using High-Affinity Glycan Ligand-Decorated Glycanoparticles. <i>Advanced Science</i> , 2023, 10, .	5.6	5
195	Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	12

#	ARTICLE	IF	CITATIONS
196	Modeling the impact of child vaccination (5-11 years) on overall COVID-19 related hospitalizations and mortality in a context of omicron variant predominance and different vaccination coverage paces in Brazil. <i>The Lancet Regional Health Americas</i> , 2023, 17, 100396.	1.5	1
197	Analytical performance of the rapid qualitative antigen kit for the detection of SARS-CoV-2 during widespread circulation of the Omicron variant. <i>Journal of Infection and Chemotherapy</i> , 2023, 29, 257-262.	0.8	4
198	Projecting the COVID-19 immune landscape in Japan in the presence of waning immunity and booster vaccination. <i>Journal of Theoretical Biology</i> , 2023, 559, 111384.	0.8	7
199	SARS-CoV-2 Breakthrough Infection after mRNA-1273 Booster among CoronaVac-Vaccinated Healthcare Workers. <i>Infection and Chemotherapy</i> , 2022, 54, 774.	1.0	3
200	Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study. <i>BMJ, The</i> , 0, , e073070.	3.0	16
201	The Preventive Role of mRNA Vaccines in Reducing Death among Moderate Omicron-Infected Patients: A Follow-Up Study. <i>Viruses</i> , 2022, 14, 2622.	1.5	2
203	Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression. <i>BMC Medicine</i> , 2022, 20, .	2.3	8
205	Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
206	Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	3
207	Economic evaluation of COVID-19 rapid antigen screening programs in the workplace. <i>BMC Medicine</i> , 2022, 20, .	2.3	2
209	Urgency and necessity of Epstein-Barr virus prophylactic vaccines. <i>Npj Vaccines</i> , 2022, 7, .	2.9	20
211	Evaluation of antibody response to SARS-CoV-2 variants after 2 doses of mRNA COVID-19 vaccine in a correctional facility. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	3
212	Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression. <i>Vaccines</i> , 2022, 10, 2180.	2.1	16
213	Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2022, , .	0.3	3
214	Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant. <i>Cell Reports Medicine</i> , 2023, 4, 100910.	3.3	5
216	Prevalence of Post-Coronavirus Disease Condition 12 Weeks After Omicron Infection Compared With Negative Controls and Association With Vaccination Status. <i>Clinical Infectious Diseases</i> , 2023, 76, 1567-1575.	2.9	20
217	Vaccination against Borna Disease: Overview, Vaccine Virus Characterization and Investigation of Live and Inactivated Vaccines. <i>Viruses</i> , 2022, 14, 2706.	1.5	1
218	The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages. <i>Virologica Sinica</i> , 2022, 37, 786-795.	1.2	12

#	ARTICLE	IF	CITATIONS
219	Pre-Existing Population Immunity and severe acute respiratory syndrome coronavirus 2 Variant Establishment and Dominance Dynamics in the United States: An Ecological Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	1
220	Real-World Effectiveness of COVID-19 Vaccines against Severe Outcomes during the Period of Omicron Predominance in Thailand: A Test-Negative Nationwide Caseâ€“Control Study. <i>Vaccines</i> , 2022, 10, 2123.	2.1	15
221	Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
222	Azapeptide activity-based probes for the SARS-CoV-2 main protease enable visualization of inhibition in infected cells. <i>Chemical Science</i> , 2023, 14, 1666-1672.	3.7	1
223	Current and Emerging Knowledge in COVID-19. <i>Radiology</i> , 2023, 306, .	3.6	30
224	Effects of COVID-19 vaccination on clinical outcomes in patients hospitalized in Internal Medicine during Omicron variant spreading.. <i>Internal and Emergency Medicine</i> , 0, , .	1.0	0
225	Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. <i>Nature Communications</i> , 2023, 14, .	5.8	54
227	Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	8
228	Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2. <i>Biomedical Journal</i> , 2023, 46, 70-80.	1.4	8
231	Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees. <i>Virologica Sinica</i> , 2023, 38, 233-243.	1.2	7
232	Rapid SARS-CoV-2 Seroprevalence Survey in Central and Western Divisions of Fiji, 2021. <i>Emerging Infectious Diseases</i> , 2023, 29, 226-228.	2.0	0
233	Vaccination with S _{pan} , an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	14
234	T Cell Immune Responses against SARS-CoV-2 in the With Corona Era. <i>Biomedical Science Letters</i> , 2022, 28, 211-222.	0.0	0
235	Safety, Efficacy, and Immunogenicity of Varying Types of COVID-19 Vaccines in Children Younger Than 18 Years: An Update of Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2023, 11, 87.	2.1	5
236	Association between vaccination status and COVID-19-related health outcomes among community-dwelling COVID-19 patients in Nara, Japan. <i>Environmental Health and Preventive Medicine</i> , 2023, 28, 7-7.	1.4	4
237	Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	7
238	A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529). <i>Vaccines</i> , 2023, 11, 224.	2.1	21
241	Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave. <i>International Journal of Infectious Diseases</i> , 2023, 128, 347-354.	1.5	7

#	ARTICLE	IF	CITATIONS
242	COVID-19 Vaccine Effectiveness Against the Omicron Variant in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2023, 118, 664-673.	0.2	3
243	COVID-19 Vaccination in Korea. <i>Infection and Chemotherapy</i> , 2023, 55, 135.	1.0	9
244	COVID-19 Vaccine Booster Dose Acceptance among Older Adults. <i>Vaccines</i> , 2023, 11, 542.	2.1	3
246	Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations. <i>Lancet Infectious Diseases</i> , The, 2023, , .	4.6	0
247	Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy. <i>Vaccines</i> , 2023, 11, 806.	2.1	1
248	Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022. <i>International Journal of Infectious Diseases</i> , 2023, 130, 182-188.	1.5	7
249	Immunogenic fusion proteins induce neutralizing SARS-CoV-2 antibodies in the serum and milk of sheep. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2023, 38, e00791.	2.1	2
250	Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational COVID-19 studies. <i>International Journal of Infectious Diseases</i> , 2023, 131, 111-114.	1.5	6
251	COVID-19 vaccines effectiveness against symptomatic disease and severe outcomes, 2021â€“2022: a test-negative caseâ€“control study. <i>Public Health</i> , 2023, 218, 84-91.	1.4	1
252	Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2024, 42, 187-194.	0.2	3
253	Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population. <i>Pathogens</i> , 2023, 12, 233.	1.2	7
255	A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. <i>Cell Reports Medicine</i> , 2023, 4, 100971.	3.3	4
256	Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone. <i>Current Issues in Molecular Biology</i> , 2023, 45, 1741-1761.	1.0	2
257	Effectiveness of mRNA vaccine against Omicron-related infections in the real world: A systematic review and meta-analysis. <i>American Journal of Infection Control</i> , 2023, 51, 1049-1055.	1.1	4
258	Cost benefit analysis of alternative testing and quarantine policies for travelers for infection control: A case study of Singapore during the COVID-19 pandemic. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	0
260	The impact of COVID-19 certification mandates on the number of cases of and hospitalizations with COVID-19 in the UK: A difference-in-differences analysis. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	0
261	Effectiveness of Inactivated Vaccine against SARS-CoV-2 Delta Variant Infection in Xiamen, Chinaâ€“A Test-Negative Case-Control Study. <i>Vaccines</i> , 2023, 11, 532.	2.1	0
262	Comparative pharmacological efficacy of COVID-19 vaccines against the variants of concerns (VOCs) of SARS-CoV-2: Recent clinical Studies on Booster dose. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, .	0.9	0

#	ARTICLE	IF	CITATIONS
263	Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France. <i>Vaccine</i> , 2023, 41, 2280-2288.	1.7	5
264	The Coming of Age of Nucleic Acid Vaccines during COVID-19. <i>MSystems</i> , 2023, 8, .	1.7	5
265	Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
266	Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). <i>Expert Review of Vaccines</i> , 2023, 22, 288-298.	2.0	4
267	Testing Whether Higher Contact Among the Vaccinated Can Be a Mechanism for Observed Negative Vaccine Effectiveness. <i>American Journal of Epidemiology</i> , 2023, 192, 1335-1340.	1.6	4
268	Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	17
270	Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. <i>Nature Communications</i> , 2023, 14, .	5.8	31
271	Evaluation of rprRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model. <i>Molecular Therapy</i> , 2023, 31, 1046-1058.	3.7	6
272	Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome. <i>Nature Communications</i> , 2023, 14, .	5.8	17
273	Applying deep learning to predict innovations in small and medium enterprises (SMEs): the dark side of knowledge management risk. <i>VINE Journal of Information and Knowledge Management Systems</i> , 2023, ahead-of-print, .	1.2	0
274	A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6369.	1.8	4
275	Transmission Characteristics and Inactivated Vaccine Effectiveness Against Transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China. <i>JAMA Network Open</i> , 2023, 6, e235755.	2.8	13
276	Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	6
277	Endogenous piRNAs Can Interact with the Omicron Variant of the SARS-CoV-2 Genome. <i>Current Issues in Molecular Biology</i> , 2023, 45, 2950-2964.	1.0	0
278	Reduced serological response to COVID-19 booster vaccine is associated with reduced B cell memory in patients with Inflammatory Bowel Disease; VARIATION (VARIability in Response in IBD Against) Tj ETQq0 0 0 rgBTd/Overlock 110 Tf 50 1		
279	A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned. <i>PLoS Pathogens</i> , 2023, 19, e1011298.	2.1	5
280	Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	2
281	Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages. <i>Nature Communications</i> , 2023, 14, .	5.8	1

#	ARTICLE	IF	CITATIONS
282	Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study. <i>International Journal of Infectious Diseases</i> , 2023, 133, 36-42.	1.5	10
283	Reply to author. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	0
284	Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. <i>Journal of Infection</i> , 2023, 87, 18-26.	1.7	7
328	Editorial: Delivering nucleic acids to immune and non-immune cells. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
334	mRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2023, 48, 515-529.	0.6	1
358	B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. , 2024, 21, 144-158.		4
368	Immunoregulatory nanomedicine for respiratory infections. , 0, , .		0